Is CRPC definition still valid in the new era of antiandrogens for mHSPC treatment?

被引：0
|
作者：
Ojeda-Claro, A. V. [1 ]
Ledo-Cepero, M. J. [1 ]
Alvarez-Ossorio, J. L. [1 ]
机构：
[1] Hosp Univ Puerta Mar, Unidad Urooncol, Cadiz, Spain
来源：
ACTAS UROLOGICAS ESPANOLAS | 2023年 / 47卷 / 09期
关键词：
PROSTATE-CANCER; CLINICAL-TRIALS; RECOMMENDATIONS; PROGRESSION; DESIGN; PSA;
D O I：
10.1016/j.acuro.2023.02.006
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：543 / 545
页数：3
相关论文
共 50 条
  • [21] Bleeding risk stratification in acute coronary syndromes. Is it still valid in the era of the radial approach?
    Ando, Giuseppe
    Costa, Francesco
    POSTEPY W KARDIOLOGII INTERWENCYJNEJ, 2015, 11 (03): : 170 - 173
  • [22] Mechanical dyssynchrony in heart failure: Still a valid concept for optimizing treatment?
    Galli, Elena
    Leclercq, Christophe
    Donal, Erwan
    ARCHIVES OF CARDIOVASCULAR DISEASES, 2017, 110 (01) : 60 - 68
  • [23] ILEOPLASTY IS STILL A VALID TREATMENT FOR RADIUM LESIONS OF THE URINARY-TRACT
    LEGUILLOU, M
    FERRIERE, JM
    MUGNIER, C
    LHENAFF, F
    JOURNAL D UROLOGIE ET DE NEPHROLOGIE, 1979, 85 (10-1): : 695 - 698
  • [24] Hypertension awareness, treatment and control in the community: Is the 'rule of halves' still valid?
    MarquesVidal, P
    Tuomilehto, J
    JOURNAL OF HUMAN HYPERTENSION, 1997, 11 (04) : 213 - 220
  • [25] Hypertension awareness, treatment and control in the community: is the ‘rule of halves’ still valid?
    P Marques-Vidal
    J Tuomilehto
    Journal of Human Hypertension, 1997, 11 : 213 - 220
  • [26] Refractory Metastatic Thyroid Cancer: Is Doxorubicin Still a Valid Treatment Option?
    Dasanu, Constantin A.
    SOUTHERN MEDICAL JOURNAL, 2010, 103 (11) : 1191 - 1192
  • [27] The obesity paradox in heart failure: is it still valid in light of new therapies?
    Froehlich, Hanna
    Frey, Norbert
    Frankenstein, Lutz
    Taeger, Tobias
    CARDIOLOGY, 2022, 147 (5-6) : 529 - 538
  • [28] Resisting resistance: Establishing new treatment options for CRPC patients
    Beedie, Shaunna
    Figg, William D.
    CANCER BIOLOGY & THERAPY, 2016, 17 (04) : 337 - 338
  • [29] New developments in the treatment of CRPC: PARP-inhibitors, immunotherapy
    Amsberg, G.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 11 - 11
  • [30] Is 3D-CRT still a valid option in radical radiochemotherapy of anal carcinoma in the era of IMRT?
    Shakir, S.
    Garant, A.
    Alshehri, S.
    Slobodan, D.
    Alcindor, T.
    Vuong, T.
    RADIOTHERAPY AND ONCOLOGY, 2017, 123 : S683 - S683
12345